Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Meta Diekstra

Meta Diekstra

As a postdoc in the Huitema Group, I work on research projects aimed at the individual treatment of children with cancer based on insights into the pharmacology of the drug. In our research group we intend to describe the pharmacokinetics of new promising drugs and existing anti-cancer treatments. To further tailor the treatment to the unique childe, we study the pharmacogenetics of multiple treatments. We investigate whether we can predict how a child will respond to chemotherapy or supportive medication based on PK/PD profiles and genetic variants.

Phone +31 6 50 00 62 89

Knowledge & experience

Specialism / subspecialism:

  • Clinical Pharmacology
  • Pharmacogenetics
  • Tyrosine kinase inhibitors
  • PK/PD/PGx studies


Working experience

2012-2017        Pharmacist/researcher, Leiden University Medical Center

2017-2021        Hospital pharmacist in training, Maastricht UMC/Zuyderland MC/Erasmus MC

2021-heden      Postdoctoral researcher, Princess Máxima Center for pediatric oncology, Utrecht   


2017     PhD (cum laude): ‘Pharmacogenetics of sunitinib in metastatic renal cell carcinoma’, Leiden University


2020-2021        Clinical Pharmacologist (ErasmusMC Rotterdam)

2017-2021        Hospital Pharmacist (Maastricht UMC/Zuyderland MC/Erasmus MC)

2012-2017        PhD research (Leiden University Medical Center)

2004-2012        Pharmacy BSc/MSc (University of Groningen)




Publications, see: PubMed.

  • Diekstra MHM, Malmberg R, Sleijfer S, van Leeuwen R. Letter to the editor: Comments on ‘A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation’. Eur J Cancer. 2020;138:54-56.
  • Diekstra MH, Swen JJ, Gelderblom H, Guchelaar H-J. A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review. Expert Rev Mol Diagn. 2016:16(5):605-18;
  • Diekstra MH, Swen JJ, Boven E, Castellano D, et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015;68(4):621-9;
  • Diekstra MH, Klümpen HJ, Lolkema MPJK, Yu H, et al. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther. 2014;96(1):81-9.